Yuan-Ya Chang

发表

NKG2A and PD-L1 expression panel predicts clinical benefits from adjuvant chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer

Y. Zhu, Le Xu, Jiejie Xu, 2022, Journal for ImmunoTherapy of Cancer.

Integrative tumour mutation burden with CD39 and PD-L1 for the prediction of response to PD-L1 blockade and adjuvant chemotherapy in muscle-invasive bladder cancer patients

Y. Zhu, Le Xu, Weijuan Zhang, 2022, British Journal of Cancer.

Immune inactivation by neuropilin-1 predicts clinical outcome and therapeutic benefit in muscle-invasive bladder cancer

Le Xu, Jiejie Xu, Hongyi Zhang, 2022, Cancer Immunology, Immunotherapy.

Kynurenine 3-monooxygenase upregulates pluripotent genes through β-catenin and promotes triple-negative breast cancer progression

Chun-Yu Liu, Hsin-Chen Lee, L. Tseng, 2020, EBioMedicine.

B7-H4 correlates with clinical outcome and immunotherapeutic benefit in muscle-invasive bladder cancer.

Le Xu, Jiejie Xu, Yu Zhu, 2022, European journal of cancer.

Significance of Kynurenine 3-Monooxygenase Expression in Colorectal Cancer

Shung-Haur Yang, Hsin-Chen Lee, Jeng-Kai Jiang, 2021, Frontiers in Oncology.

Immunosuppressive tumor-associated macrophages expressing interlukin-10 conferred poor prognosis and therapeutic vulnerability in patients with muscle-invasive bladder cancer

Y. Zhu, Le Xu, Jiejie Xu, 2022, Journal for ImmunoTherapy of Cancer.

TIGIT and PD-1 expression atlas predicts response to adjuvant chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer

Le Xu, Jiejie Xu, Li Liu, 2022, British Journal of Cancer.

Stromal Tumor-Associated Macrophage Infiltration Predicts Poor Clinical Outcomes in Muscle-Invasive Bladder Cancer Patients

Le Xu, Jiejie Xu, Shengming Jin, 2022, Annals of Surgical Oncology.

CD103+CD8+ tissue-resident memory T cell infiltration predicts clinical outcome and adjuvant therapeutic benefit in muscle-invasive bladder cancer

Y. Zhu, Le Xu, Jiejie Xu, 2022, British Journal of Cancer.

Systemic inflammation score predicts postoperative prognosis of patients with clear-cell renal cell carcinoma

Jianqing Xu, L. Xu, J. Xu, 2015, British Journal of Cancer.

Integrating angiogenesis signature and tumor mutation burden for improved patient stratification in immune checkpoint blockade therapy for muscle-invasive bladder cancer.

Y. Zhu, Le Xu, Jiejie Xu, 2023, Urologic oncology.

Gender disparities in clinical outcomes of urothelial carcinoma linked to X chromosome geneKDM6Amutation

Le Xu, Jiejie Xu, Yu Zhu, 2023, BMJ Oncology.

Integrative score based on CDK6, PD-L1 and TMB predicts response to platinum-based chemotherapy and PD-1/PD-L1 blockade in muscle-invasive bladder cancer

Le Xu, Jiejie Xu, Yu Zhu, 2024, British journal of cancer.

RAD51 Expression as a Biomarker to Predict Efficacy of Platinum-Based Chemotherapy and PD-L1 Blockade for Muscle-Invasive Bladder Cancer.

Yu Zhu, Weijuan Zhang, Zewei Wang, 2024, Journal of immunotherapy.

Integration of CD4+ T cells and molecular subtype predicts benefit from PD‐L1 blockade in muscle‐invasive bladder cancer

Le Xu, Yu Zhu, Weijuan Zhang, 2024, Cancer science.

TP53 disruptive mutation predicts platinum‐based chemotherapy and PD‐1/PD‐L1 blockade response in urothelial carcinoma

Le Xu, Jiejie Xu, Yu Zhu, 2024, The Journal of pathology.

POLQ identifies a better response subset to immunotherapy in muscle‐invasive bladder cancer with high PD‐L1

Le Xu, Jiejie Xu, Yu Zhu, 2024, Cancer medicine.

Immune inactivation by VISTA predicts clinical outcome and therapeutic benefit in muscle-invasive bladder cancer

Y. Zhu, Weijuan Zhang, Zewei Wang, 2023, BMC Cancer.